Blazekovic I, Samija I, Perisa J, Gall Troselj K, Regovic Dzombeta T, Radulovic P
Biomedicines. 2024; 12(3).
PMID: 38540091
PMC: 10968519.
DOI: 10.3390/biomedicines12030477.
Li W, Yu W, Du J, Teng D, Lin Y, Sui G
Front Endocrinol (Lausanne). 2023; 14:1140360.
PMID: 37305060
PMC: 10254395.
DOI: 10.3389/fendo.2023.1140360.
Attia A, Hussein M, Issa P, Elnahla A, Farhoud A, Magazine B
Int J Mol Sci. 2022; 23(24).
PMID: 36555268
PMC: 9779545.
DOI: 10.3390/ijms232415626.
Wei X, Wang X, Xiong J, Li C, Liao Y, Zhu Y
Biomed Res Int. 2022; 2022:9959649.
PMID: 35647194
PMC: 9132653.
DOI: 10.1155/2022/9959649.
Longheu A, Canu G, Cappellacci F, Erdas E, Medas F, Calo P
J Clin Med. 2020; 10(1).
PMID: 33379135
PMC: 7794904.
DOI: 10.3390/jcm10010070.
Association between BRAF mutation and the clinicopathological features in incidental papillary thyroid microcarcinoma: A single-center study in Turkish patients.
Sezer H, Uren N, Yazici D
North Clin Istanb. 2020; 7(4):321-328.
PMID: 33043255
PMC: 7521097.
DOI: 10.14744/nci.2020.69586.
Molecular characterisation and clinical correlation of papillary thyroid microcarcinoma.
Sama M, Grosso E, Mele C, Laurora S, Monzeglio O, Marzullo P
Endocrine. 2020; 71(1):149-157.
PMID: 32621051
DOI: 10.1007/s12020-020-02380-8.
Does the Site of Origin of the Microcarcinoma with Respect to the Thyroid Surface Matter? A Multicenter Pathologic and Clinical Study for Risk Stratification.
Tallini G, De Leo A, Repaci A, de Biase D, Bacchi Reggiani M, Di Nanni D
Cancers (Basel). 2020; 12(1).
PMID: 31963890
PMC: 7016743.
DOI: 10.3390/cancers12010246.
Genomic and Transcriptomic Characterization of Papillary Microcarcinomas With Lateral Neck Lymph Node Metastases.
Perera D, Ghossein R, Camacho N, Senbabaoglu Y, Seshan V, Li J
J Clin Endocrinol Metab. 2019; 104(10):4889-4899.
PMID: 31237614
PMC: 6733494.
DOI: 10.1210/jc.2019-00431.
Risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: a study of 1,587 patients.
Zheng X, Peng C, Gao M, Zhi J, Hou X, Zhao J
Cancer Biol Med. 2019; 16(1):121-130.
PMID: 31119052
PMC: 6528461.
DOI: 10.20892/j.issn.2095-3941.2018.0125.
Long-term outcomes of follicular variant vs classic papillary thyroid carcinoma.
Henke L, Pfeifer J, Baranski T, DeWees T, Grigsby P
Endocr Connect. 2018; 7(12):1226-1235.
PMID: 30352402
PMC: 6240143.
DOI: 10.1530/EC-18-0264.
Predictive Value of BRAF Mutation for Lymph Node Metastasis in Papillary Thyroid Cancer: A Meta-analysis.
Song J, Sun S, Dong F, Huang T, Wu B, Zhou J
Curr Med Sci. 2018; 38(5):785-797.
PMID: 30341513
DOI: 10.1007/s11596-018-1945-7.
Molecular markers in well-differentiated thyroid cancer.
DCruz A, Vaish R, Vaidya A, Nixon I, Williams M, Vander Poorten V
Eur Arch Otorhinolaryngol. 2018; 275(6):1375-1384.
PMID: 29626249
DOI: 10.1007/s00405-018-4944-1.
EGFR inhibition enhances the antitumor efficacy of a selective BRAF V600E inhibitor in thyroid cancer cell lines.
Jia Y, Zhang C, Hu C, Yu Y, Zheng X, Li Y
Oncol Lett. 2018; 15(5):6763-6769.
PMID: 29616135
PMC: 5876456.
DOI: 10.3892/ol.2018.8093.
Relationship Between F-fluorodeoxyglucose Accumulation and the BRAF Mutation in Papillary Thyroid Cancer.
Chang J, Park K, Heo J, Jung S, Liu L, Kim S
World J Surg. 2017; 42(1):114-122.
PMID: 28808756
DOI: 10.1007/s00268-017-4136-y.
The Genetics of Papillary Microcarcinomas of the Thyroid: Diagnostic and Prognostic Implications.
Cunha Rodrigues A, Penna G, Rodrigues E, Castro P, Sobrinho-Simoes M, Soares P
Curr Genomics. 2017; 18(3):244-254.
PMID: 28659720
PMC: 5476952.
DOI: 10.2174/1389202918666170105094459.
Association between BRAF mutation and the clinicopathological features of solitary papillary thyroid microcarcinoma.
Lu H, Qiu T, Ying J, Lyn N
Oncol Lett. 2017; 13(3):1595-1600.
PMID: 28454296
PMC: 5403221.
DOI: 10.3892/ol.2017.5661.
Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis.
Liu C, Chen T, Liu Z
World J Surg Oncol. 2016; 14(1):241.
PMID: 27600854
PMC: 5012084.
DOI: 10.1186/s12957-016-0979-1.
Predicting Extrathyroidal Extension in Patients With Papillary Thyroid Microcarcinoma According to a BRAF Mutation.
Lee D, Hwang S, An J, Son K, Baek S, Kim S
Clin Exp Otorhinolaryngol. 2016; 10(2):174-180.
PMID: 27416738
PMC: 5426396.
DOI: 10.21053/ceo.2015.01655.
Diagnostic value of BRAF (V600E)-mutation analysis in fine-needle aspiration of thyroid nodules: a meta-analysis.
Su X, Jiang X, Xu X, Wang W, Teng X, Shao A
Onco Targets Ther. 2016; 9:2495-509.
PMID: 27175084
PMC: 4854268.
DOI: 10.2147/OTT.S101800.